Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 1.08M
2: EX-10.1 Material Contract HTML 133K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
12: R1 Cover Page HTML 74K
13: R2 Condensed Consolidated Balance Sheets HTML 128K
14: R3 Condensed Consolidated Statements of Operations HTML 102K
15: R4 Condensed Consolidated Statements of Comprehensive HTML 46K
Loss
16: R5 Condensed Consolidated Statements of Stockholders? HTML 79K
Equity
17: R6 Condensed Consolidated Statements of Cash Flows HTML 120K
18: R7 Description of Business and Basis of Presentation HTML 24K
19: R8 Summary of Significant Accounting Policies HTML 30K
20: R9 Other Financial Statement Information HTML 107K
21: R10 Commitments and Contingencies HTML 38K
22: R11 Capital Stock HTML 24K
23: R12 Equity Incentive Plans HTML 48K
24: R13 Net Loss Per Share HTML 34K
25: R14 Subsequent Events HTML 20K
26: R15 Summary of Significant Accounting Policies HTML 43K
(Policies)
27: R16 Other Financial Statement Information (Tables) HTML 120K
28: R17 Commitments and Contingencies (Tables) HTML 33K
29: R18 Equity Incentive Plans (Tables) HTML 50K
30: R19 Net Loss Per Share (Tables) HTML 33K
31: R20 Summary of Significant Accounting Policies - HTML 19K
Additional Information (Detail)
32: R21 Other Financial Statement Information - HTML 47K
Available-for-Sale Securities (Details)
33: R22 Other Financial Statement Information - Additional HTML 36K
Information (Detail)
34: R23 Other Financial Statement Information - HTML 36K
Contractual Maturities of Marketable Securities
(Details)
35: R24 Other Financial Statement Information - Schedule HTML 28K
of Inventory (Detail)
36: R25 Other Financial Statement Information - Schedule HTML 34K
of Accrued Compensation and Related Benefits
(Detail)
37: R26 Other Financial Statement Information - Schedule HTML 40K
of Accrued Expense And Other Current Liabilities
(Detail)
38: R27 Other Financial Statement Information - Schedule HTML 25K
of Changes in the Reserve for Product Warranties
(Detail)
39: R28 Other Financial Statement Information - Revenue HTML 22K
Recognition (Details)
40: R29 Other Financial Statement Information - Schedule HTML 30K
of Revenue by Source (Detail)
41: R30 Other Financial Statement Information - Schedule HTML 35K
of Revenue by Geographic Region (Details)
42: R31 Commitments and Contingencies - Additional HTML 24K
Information (Detail)
43: R32 Commitments and Contingencies - Summary of HTML 40K
Company's Operating Lease Liabilities (Detail)
44: R33 Commitments and Contingencies - Summary of HTML 22K
Additional Information Related to Operating Leases
(Detail)
45: R34 Capital Stock - Additional Information (Detail) HTML 32K
46: R35 Equity Incentive Plans - Additional Information HTML 29K
(Detail)
47: R36 Equity Incentive Plans - Recorded Stock-Based HTML 28K
Compensation Expense in the Condensed Consolidated
Statement of Operations (Details)
48: R37 Equity Incentive Plans - Summary of RSU Activity HTML 41K
(Detail)
49: R38 Equity Incentive Plans - Summary of Company's HTML 41K
Stock Option Activity (Details)
50: R39 Net Loss Per Share - Shares of Common Stock HTML 35K
Equivalents Were Excluded From The Computation of
Diluted Net Loss Per Share (Details)
51: R40 Subsequent Events (Details) HTML 26K
54: XML IDEA XML File -- Filing Summary XML 95K
52: XML XBRL Instance -- txg-20220630_htm XML 1.08M
53: EXCEL IDEA Workbook of Financial Reports XLSX 82K
8: EX-101.CAL XBRL Calculations -- txg-20220630_cal XML 179K
9: EX-101.DEF XBRL Definitions -- txg-20220630_def XML 258K
10: EX-101.LAB XBRL Labels -- txg-20220630_lab XML 1.06M
11: EX-101.PRE XBRL Presentations -- txg-20220630_pre XML 571K
7: EX-101.SCH XBRL Schema -- txg-20220630 XSD 99K
55: JSON XBRL Instance as JSON Data -- MetaLinks 291± 441K
56: ZIP XBRL Zipped Folder -- 0001770787-22-000049-xbrl Zip 496K
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Serge Saxonov, the Chief Executive Officer of 10x Genomics, Inc. (the “Company”), hereby certify, that, to my knowledge:
1.The
Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.